超出印刷页面|2022年1月24日

曾经学习过艰难的方式吗?

资料来源:生命科beplay老版学领导
Rob Wright Author Page

经过罗克赖特,主要编辑,生命科学领袖beplay老版
在推特上关注我@rfwrightlsl.

Bernard Coulie.
Bernard Coulie,M.D.,Ph.D.,Plant Therapeutics总裁兼首席执行官

Bernard Coulie,M.D.,Ph.D.,在他的第一次启动中学会了一个艰难的教训。该公司Actogenix N.v.是比利时的小生物技术,是使用益生菌以定义的方式刺激微生物组。该公司是第一个尝试这个的,因此,在处理FDA和EMA时,它变得有点噩梦,因为他们不知道该产品应该如何分类。“最终,它最终被认为是一种基因治疗,尽管从未插入了基因,”他解释道。

According to Coulie, when there’s nothing already in the market, not only are you challenged with having to pave the regulatory and safety paths, you have to embark on vast physician, patient, and provider education, which requires lots of money, along with investor conviction to play a long game. “We ended up selling the company because our European VCs were no longer willing to fund it.” That sale involved billionaire R.J. Kirk, whom Coulie recalled meeting somewhere in 2013. “R.J. came up to me and said that we were doing what he wanted to do, and that he was going to buy us. I was like, I don’t think that will happen.” But a year later, ActoGeniX had no cash left, so Coulie called Kirk. Ultimately, they came to an agreement in early 2015 for half cash and half stock, totaling about $60 million. Coulie stayed on for a couple weeks until an agreement was reached for him to leave. “Sometimes you have to make decisions and direct a company toward an exit you might not have wished for when you started,” he concedes.

但是你不能让一个好的企业家失望,特别是在利用教训中获得的智慧获得了一个认真的人。今天,Coulie是Pliant Therapeutics(纳斯达克:PLRX)的总裁兼首席执行官,以及我们即将到来的特色文章的主题在2月份问题。beplay官网注册现在订阅为了确保您阅读整个故事,成功建设这家纤维化疾病的成功公司,与科学家带来领导它。